Okay, great. Hi, everyone. I'm Evie Koslosky, Life Science Tools and Diagnostics Analyst here at Goldman Sachs. I'm here today with Caris Life Sciences. They're going to start with a presentation, then we'll open it up to Q&A at the end. Okay. Evie, thank you. I'm Brian Brille. I'm Vice Chairman of Caris Life Sciences. I'm here with Milan Radovich, our CSO, and Luke Power, our CFO. I think I would just start by saying that while we've been at this since 2008, when our founder had this vision around precision medicine and precision oncology, I would say that we see more opportunity in the market in terms of working with cancer centers, both at the institutional level as well as the individual oncologist level, than we've ever seen. This whole revolution in molecular medicine and transitioning from sort of the previous way of looking at things to a true state-of-the-art in molecular medicine from both a clinical and research perspective is happening. It's happening very quickly, we think we have huge edges as a result of building this platform over many, many years. I would suggest that these platforms really matter. The ability to be a partner and deliver the best technology at the individual oncologist level and to be a partner with the institution is what it is going to take to really be one of the true leaders in this space. I think that's defined by technology, it's defined by scale, it's defined by datasets, importantly, in this area. Remember, these are real AI type of companies, all of this needs to be delivered through a channel. We've had, we think, the best technology from the beginning. We're whole exome, whole transcriptome, and we're moving towards whole genome, which we'll talk about. In terms of scale, we profiled over 200,000 patients last year, that's going up very significantly. Our dataset now is over a million profiles, most of which are whole exome, whole transcriptome, the vast majority of which are matched with clinical outcomes information. The channel is very important. You've got to reach the physicians. You've got to be in a position to be a real partner with the institutions. We're reaching over 6,000 ordering oncologists, we're very excited about how the platform is progressing as well. This leadership from a technology perspective, we're the only company with an FDA-approved whole exome, whole transcriptome technology that has helped us with our partnerships, it's helped us with research, it's also helped us with our reimbursement. We're expanding to whole genome, initially with Caris ChromoSeq, which we launched recently in the heme area, as well as with our multi-cancer early detection, Caris Detect. We go to market in a highly differentiated way. We support the physicians from a clinical perspective. We set up precision oncology programs, and we also are a very attractive research partner through the Caris Precision Oncology Alliance, which is now at 100 member institutions. Now we're launching new products. We just launched Caris ChromoSeq, which is a whole genome solution for heme profiling, which Milan will speak about. Caris MI Clarity is very exciting. It's a digital pathology solution, very quick as a result, uses our extensive data sets, and this is for early-stage breast cancer. The data asset that we have accrues in scale, relevance, and value all of the time. We're over a million genomic profiles, and these AI tools that we're using benefit from this. This is driving not only our internal R&D, but also our attractiveness as a partner. One of the key things about our platform is our profitability. That gives us huge leverage in terms of the ability to invest. We're investing in our commercial team. We're expanding the size. We're doing a variety of different things there, which we think are going to really help us with respect to the upside in our clinical case volume as well as continuing to invest in our product pipeline from MCED over on the right here. From MCED, which has been a passion project of our founder since the very beginning and we think opens up an entirely new world in terms of reaching basically everybody, not just late-stage cancer patients. MRD, our tissue naive and tissue-informed approaches, Milan will speak about. The other thing we'd say about our platform, because we are so broad and so deep in the information that we generate, we've been looking at this for a number of years now. This gives us signals and information around all disease states, autoimmune, neurology, CNS, cardiology, et cetera, which we're extremely excited about. Our data set, you can see, continues to grow very nicely. We think we have the largest transcriptome data set in the world at 728,000 transcriptomes. The vast majority of this over a million size data set is matched with clinical outcomes. We also have an extraordinary set of digital pathology slides. Every slide that comes in now is digitized. This has become a real factory in terms of the generation of that data set. In investor meetings, we get a lot of questions around the market. Is it getting penetrated? Is it slowing down? I say it's as exciting as it's ever been. The TAM is large, and this is just for therapy selection. It's large. It's growing. By our count, it's only about 35%-40% penetrated. Earlier staging is coming into play as well as a broader set of therapeutics, et cetera. Not to mention the fact that we think we're pushing the definition itself of CGP, comprehensive genomic profiling, beyond larger panels into whole exome, whole transcriptome, and now whole genome. Molecular profiling has emerged as standard of care. There's no question about that. It wasn't that long ago at ASCO when a number of the podium presenters were talking about it's not a question about whether every single patient needs to be profiled, they do. It's just a question of what technology you use and what partner you choose. This then relates to precision oncology programs. We're seeing a whole new generation of very thoughtful cancer center directors coming into place, and they're thinking about, okay, how do I not just get all of my physicians profiling consistently and systematically, but how do I set up a precision oncology program that generates the right data, that has the best clinical outcomes? This is hard. We have a cancer center director sitting here. I don't have to tell Steve how hard that job is. The whole notion of being able to set up a program, a programmatic approach that does this is not easy, and that's how we think about our business. That's why we have 50 PhDs in the field, molecular science liaisons that are deployed for that purpose. We have account managers. We have a highly matrixed set of people supporting the cancer center directors, and their institutions to deploy these sorts of programs. For these reasons, we're very excited about the trends, about the future, and this notion of cancer centers moving towards institutional decisions at the top of the house, not just individual oncologists doing whatever it is he or she wants to do, I think is very important, and it relates to our ability to deliver all of these capabilities. This is a little bit on our channel. We've always had a patient-first philosophy, even the move a number of years ago to whole exome, whole transcriptome was motivated not for the data per se or the data applications, but by clinical utility and the notion that this is the best thing for the patient today, and it's the best things for the patients in the future as well. Our platform today is about 270 people, field-based team. That number had gone down a little bit during the period of time right before the IPO when we were capital constrained. We have the opportunity now to reinvigorate that, invest in that business. That's what we're going to do. We have a new chief commercial officer who's highly dynamic, he's adding people. We're hiring. We've increased the number of territories significantly and will continue to do so. We're also putting product specialists in the field that can be very articulate and helpful with respect to supporting the different product capabilities. We also have a strategic coverage team, which we're quite proud of. We think we cover the top of the house extremely well across the various cancer centers. Covering the cancer center directors, their deputies, the committees, the various department heads. There's an art to this, and it requires an investment and one that we have made. The Precision Oncology Alliance, which is really the only collaboration like it in precision oncology, I would argue precision medicine as well. We're at 100 institutions. We feel there's more that we can do with these sites, we're very eager to take this to the next level. It's dynamic. We have new people still joining. This group represents about 4,000 oncologists, and about 650,000 new cancer patients annually. There's a power in this collaboration that the institutions are very excited about. At the heart of it is their ability to use our data set and do research with us and to publish together. I'll turn this over to Milan, but basically, we're super excited about our technology leadership, our pipeline, which Milan will tell us about. The channel, I think, is very special. There are very few platforms that have all of these things. Finally, the financial profile that we have with a very strong top line growth, profitability as well, which puts us in a position. We announced a share repurchase this morning, which is not a super strategic thing, but it's certainly indicative of our ability, given our financial position and our profitability, to continue to invest in the product pipeline and the channel, as well as get into the market and signal to the market our confidence level in the future for this company. All right. Thanks. Milan? Great. Thank you, Brian. Thank you very much. If I had it my way, I'd give this presentation on the beach. It's a pleasure to have you guys here today. I'm excited to give little fun updates on our Caris technology platform. As many of you know, Caris is well known for being as comprehensive as possible with the sequencing. We've really standardized on this concept of looking at every single gene in the genome and the transcriptome since 2019. We do it for two reasons. One, to leave no stone unturned to identify a drug or a clinical trial for a patient. We know that many of the patients we serve are patients with late-stage disease who are looking for options for their care, and we want to make sure that they have the best shot for their treatment. Two, as Brian already alluded to, while our number one goal is to help the patient of today, we can also use that data to help the patient of tomorrow. We've amassed this huge data set that has been used extensively for academic research. We had 32 ASCO abstracts, as many of you were there. We used it for our internal development and as well as in a partnership with pharma, and I'll touch on that. Building on our platform, while we've made our mainstay headway in therapy selection for late-stage disease on tissue, we built the platform to really cover the continuum of the entire disease course. Building a liquid biopsy platform that covers therapy selection. We're currently validating as well for MRD. I'll touch on a little bit later, building a platform for early detection, being able to detect cancers at their earliest stages, while all the while continuing our strong position in doing a tissue-based sequencing for therapy selection with our FDA-approved MI Cancer Seek. From a sequencing perspective, as my colleagues like to make fun of me, I always like to say we always look at the entire kit and caboodle. Every gene in the genome, both at the DNA and the RNA level, as I already mentioned. When you are doing this comprehensive amount of sequencing, you really can pick up an entire litany of analytes in the tissue that are important for therapy selection. Basic things like mutations, copy number, and fusions, but more complex things like multi-gene signatures that help us predict, for example, the tissue of origin, where the cancer came from, or help predict a chemotherapy outcome or immunotherapy outcome. We're the only test on the market that is FDA approved to do whole exome and transcriptome, and we do this on every single patient, and it's part of our standard of care. One of the cool things as well is that this large amount of data that we collect allows us to be really versatile. As I mentioned, new clinical trials, new biomarkers come out almost every single week. We have a whole team dedicated that updates a report on a weekly basis with the latest and greatest in evidence. When a patient is sequenced with Caris, we're not missing anything. If there's a drug out there, we're going to find it's again, part of our ethos and our approach to providing the best standard of care. In addition to that, we do, as you guys are well aware, we have tons of FDA approvals coming out. One of the parts of Caris standard of care is we have this lookback program so that when a new biomarker gets approved, we look back usually about a year, identify all the patients that were positive for that particular biomarker, and then we contact the physician and let them know. This is not any extra cost. It's just part of our standard care. We did this recently with a variety of the drugs that have been FDA approved, like capivasertib and evolocumab. We'll do it for tacrolimus. We'll do it for all these novel new agents as well. As I mentioned as well, having this comprehensive sequencing allows us to do much more intricate types of gene signatures. I'll touch on them in a couple slides, but one piece I wanted to point out here on the right side is a paper we just published a few weeks ago on the importance of whole exome for TMB. Some of you may be familiar with TMB. TMB stands for tumor mutational burden. As I used to explain to patients, it's a measure of how messed up the cancer is, how many mutations are in that cancer genome. What we know is that cancers that have higher mutation burden begin to look more and more foreign to the immune system. However, we have this checkpoint called PD-L1 that acts like a camouflage that allows the tumor to evade the immune system. However, when we use drugs that block that camouflage, things like pembrolizumab, when these camouflage is unmasked, these cancers that have a higher mutation burden that look more foreign actually are more responsive to immunotherapy. It's been known in the academic literature for a long time that whole exome sequencing is the best way to assess TMB, and by definition, we're sequencing every gene in the genome that can make a mutated neoantigen that could be presented to the immune system. What folks have done, traditionally, they'll do gene panels, and they'll estimate TMB based on a subset, so maybe on 300 genes or 700 genes or whatnot. What we show in this paper is not only the importance of the accuracy of TMB by doing whole exome but actually showing that this accuracy leads to better outcomes. This is the first time it's ever been demonstrated that having whole exome-based TMB, when you compare it to panels, results in about 10%-15% discordance, and that discordance results in inferior outcomes compared to using whole exome sequencing. Again, further refining this position, the importance of doing this comprehensive sequencing. As mentioned, our whole exome transcriptome is FDA approved, the only FDA-approved whole exome and transcriptome on the market, this doesn't really change our ethos. Our ethos has stayed the same whether we're FDA approved or not, what it does is gives us the stamp of approval that the FDA has faith in our robustness, our sensitivity, our specificity in all our metrics. This was a massive submission, fantastic work by the team who achieved this FDA approval. It was approved for CDx indication across these various drugs you see here, as well as pan-cancer indication with MSI-H. Building on our legacy of whole exome transcriptome on tissue, we also do this on blood with our assay, Caris Assure. It's two assays in one. It's a whole exome and transcriptome on the plasma, looking at all tumor-derived DNA and RNA, but as well as on the buffy coat or the white blood cell layer to analyze for incidental germline mutations, meaning mutations that patients may be born with that predispose them to develop cancer, as well as mutations from something called clonal hematopoiesis or CHIP. For those of you, I think most of you are going to be familiar with this, but if you're not, you can impress your friends or neighbors later. CHIP stands for clonal hematopoiesis of indeterminate potential. What these are naturally occurring mutations in our white blood cells that tend to increase with age, smoking, and prior chemotherapy exposure. What we know is that many of these mutations occur in hotspots, certain hematopoietic hotspots, genes like JAK2, ASXL1, and others. What we know, though, is that a subset of them can occur in classical oncogenes, so genes like K-RAS or TP53 or BRCA1 or BRCA2. What happens is when these mutations occur in these oncogenes, they are a source of interference, meaning that if you couldn't differentiate between CHIP and a tumor-derived mutation, a doctor may make an inappropriate action based on a mutation that didn't actually come from the cancer but came from the normal white bloods. We don't want to do that. That's not treating patients well. The only way to definitively determine that is by sequencing the white blood cell layer directly. We published a paper last year in Clinical Cancer Research that identified that 42% of patients had CHIP alterations. This is consistent with the literature. What we see on this graph is on the x-axis is every gene we've seen a CHIP mutation in, and y-axis says if we see a mutation in this gene, how often is it CHIP origin? These genes in light blue, genes like CHEK2, BRCA2, ARID1A, NF1, and so on, are genes that if you didn't know was of CHIP origin could lead you to either an inappropriate therapy association, diagnostic association, or prognostic association. As I used to tell oncology fellows in the clinic is, you want to use liquid biopsies to identify markers to give an actual therapy. What you don't want to do is give a patient a wrong drug based on, again, mutation not coming from the cancer cell, but coming from the white blood cells. As mentioned, we continue to also utilize this massive data set to develop really cutting-edge AI signatures. As I like to tell people, Caris was doing AI before it was cool, before ChatGPT wrote your kids' essays. It's been in our DNA for a long time. We've always had a large staff of PhD-level computational scientists and mathematicians at Caris. A particular algorithm we've been very proud of that we first launched several years ago in our first version. We're now on our third version called GPSai. What this does is it takes that sequencing data and determines what tissue did the cancer come from. It was originally developed for Cancer of Unknown Primary, meaning, you have a patient with cancer, but they do not know where it came from. It is a really scary diagnosis. Dr. Nimer can tell you about this. Your doctor comes in the room and says, "Hey, you have cancer. It looks bad, and we do not know where it is from." That is a problem because if you do not know where it is from, the diagnosis is the foundation of all cancer treatment. It dictates everything that is done after that, every treatment that is done after the diagnosis. Not having a good diagnosis is scary. But what we have also come to realize is this test has actually been equally helpful in identifying misdiagnosed cases. Every day at Caris, we sequence roughly 700-ish cases, and about one to five or so come in where the algorithm says it is a different diagnosis on the path report. When we get that discrepancy, our pathologist will do the additional workup to get to a better diagnosis. This is a very robust assay. It was trained on almost 295, somewhere in the upper 200,000 cases. It is 84% accuracy for CUP and 95% accuracy across over 90 tumor types. We have also, due to time, I cannot go through all this, but we also developed additional algorithms for chemotherapy benefit, for a variety of IO therapy benefit as well, across a variety of different tumor types. Giving some updates on pipeline. An area that many of you are well aware that Caris is very excited about is for early detection. We developed a test called Caris Detect based on whole genome sequencing, a high-depth whole genome for the early detection of cancer. The really advantageous approach of taking whole genome sequencing is that detecting cancer is a shots on goal problem. You have got a very small number of cancer molecules and a large pool of normal. Taking as many shots on goal to detect a cancer signal gives you the best chance at optimal sensitivity and specificity. We have found whole genome sequencing to provide really significant advantages there. We have press released and presented on our earnings call our first case control data, we call Achieve 1, on 3,000 individuals, so 1,000 cancers and 2,000 normals, and achieved a Stage 1-2 sensitivity of 60.3% while maintaining a specificity of 99.2%. You can tell, and many of you who are already aptly familiar with the space, there is considerably better Stage 1-2 sensitivity than what you are currently seeing on the market. I want to point out cancers like breast and prostate performing quite well. Obviously, the importance of early detection is you have got to detect it early for these tests to be beneficial, and we are very supportive of this. We are continuing to generate additional data. We have a second core of 25,000 individuals that is currently accruing, and there will be more to come in this space. Also, just a few weeks ago, we launched Caris ChromoSeq. This is a whole genome test for hematological malignancies, initially launched for AML, MDS, and MPN. Originally published in the New England Journal of Medicine in 2021 by WashU, where we exclusively licensed it and then further improved upon this test and now have launched it. It's been a phenomenal test. Seven-day turnaround time, being able to pick up every variant needed for the appropriate diagnosis and treatment of hematological malignancies. It replaces the need for multiple smaller tests that are currently being done for hematological patients into one test. Feedback has been overwhelmingly positive on the ease, turnaround time, and the amount of comprehensive information that this test is giving oncologists who treat heme cancers. We continue to work additional parts of our pipeline. We launched MI Clarity also a few weeks ago, which is our test for breast cancer recurrence. Think of it as a replacement for Oncotype. Does a fantastic job in detecting early recurrence in the first five years, but does a really differentiates in the late recurrence, being able to detect which patients are high risk of relapse in 5- 15 years out from initial diagnosis. This is an initial path predictor. No sequencing here. It's a AI on H&E image, turns around very quickly. It turns around in a day, and providing really robust information. We're also in the development of our MRD approach, both a tumor-naive approach using our whole exome and transcriptome liquid biopsy, as well as a whole genome-based tumor-informed approach. Moving on to Pharma. Pharma has three major pillars in how we support pharma. Core biopharma services, which is traditional profiling of samples from pharma, whether on clinical trials or correlative analyses, as well as being able to support CDx engagements and identify patients who are positive for particular biomarkers for those clinical trials. We have a strategic data pillar. As Brian mentioned, amassed now over a million patients sequenced, with a majority having whole exome and transcriptome with clinical outcomes, and this is obviously really powerful for pharma research. Caris Discovery, which is our division of Caris that's focused on utilizing our data, tissue, and proprietary proteomics technologies to identify novel drug targets. Caris Discovery had fantastic news at the end of last year with Genentech, actually to our knowledge, our largest pharma deal to date, being able to partner with Genentech to identify novel drug targets for refractory cancers. Always like to point out the Genentech folks have been an absolute joy to work with. Their scientists are phenomenal. Our groups work very closely together, advancing the science here, utilizing their technologies to identify these novel drug targets. With that, I'll hand it off to my esteemed colleague, Mr. Power. Thanks, Milan. I'll go through this relatively quickly. All the numbers here have been disclosed publicly, so I think everyone's aware of these. We continue to have strong revenue performance, obviously in Q1 with the 79% growth primarily coming from the molecular profiling business, which is kind of our key unit. We've always been clinically focused, the pharma portion of our business is continuing to grow from a smaller starting point. When you look at molecular profiling, the kind of key thing that you have to focus on is there's two parts of the equation. There's the P times V. From a pricing standpoint, from an ASP standpoint, what we've been able to do over the last year was demonstrate this long-term approach that we take with our technology and having the reimbursement catch up. Historically, Caris has always kind of put the assay first and then saw reimbursement for that after the fact. Again, it's the right thing to do for the patient. Years ago, we went to a 500-gene panel before anyone else was doing even 100 genes. And then we did the exact same thing with whole exome, whole transcriptome, and the reimbursement catches up because the clinical utility is there, and obviously, it's the right thing to do. From a revenue standpoint, we continue to demonstrate very strong performance since we IPO'd last year. With overall financial performance as well, because of the reimbursement uplift and because of the focus on technology, we're also demonstrating really good operating leverage. You can see that throughout the P&L for us, where we have a gross margin in the 65% range. Again, this is while you're doing whole exome, whole transcriptome, which is not the cheapest thing to do, but again, it's the right thing to do for the patient, and also having positive adjusted EBITDA and positive free cash flow. Since we've IPO'd, we've obviously had positive free cash flow for each of the four quarters. What we're going to do this year, and what we've communicated previously is we're going to utilize that positive free cash flow and reinvest it in the business. That's kind of the attitude for this year, is the reinvestment attitude. Last year was just demonstrating the profitability. We wanted to go IPO. We wanted to demonstrate the financial strength of the company, and now we're going to reinvest it. Obviously, we announced the share repurchase this morning, just showing how strong we are from an operating leverage standpoint. As you go into the molecular profiling business unit itself, there's two components to that. There's obviously the tissue components, which we've been very strong in. It's our legacy product, but also the blood component, which is kind of newer market for us, and we've been going for about two years now. We continue to see great penetration in liquid. Obviously, in the kind of high 50% growth range in Q1. It's a smaller N from a starting standpoint, but we continue to see great penetration there. From a tissue standpoint, it's our legacy product. We definitely think there's opportunities to continue to expand that growth, and that's kind of where the focus of our investment is this year from a molecular profiling standpoint. Brian touched on this earlier. One of the key things we're investing in is the sales force, because obviously with our financial profile, the returning investment is obviously a lot differentiated than what others are doing out there. We're going to continue to expand that with the goal of getting to 300 salespeople, hopefully by the end of Q2. Continuing to expand the territories. We went to 146. I think the next step for us is to get that to 175 and continue to get penetration across the broader network itself. We continue to focus on, obviously, EHR integrations. We're in a great space and place where 70% of our orders are coming in electronically. We continue to make the investment there on that side of the team. From an overall P&L standpoint, the key items I'll point out on this are obviously the adjusted EBITDA and the free cash flow. That's very unique given our scale and how long we've been around. It's not the first time we've actually achieved this. Back in 2018, we also achieved positive free cash flow, but we decided to do the reinvestment and the reinvestment in the sales force, and obviously, that paid off with the technology focus of going to whole exome, whole transcriptome. From a performance standpoint, obviously, one of the key things from the equation standpoint is the ASP. Our MI Cancer Seek, the FDA-approved tissue assay, is priced at $8,455 on the clinical lab fee schedule. We feel very good about that pricing. Our Caris Assure assay is priced up for $3,649. One of the key things that we're going to focus on over the next one to two years is taking the same approach that we took with tissue and applying it to liquid. What does that mean? It means actually taking our liquid assay through New York State approval, which we obviously publicly announced. We've submitted that and we're waiting on it. We're taking that assay to the FDA, and once we get to the FDA approval, then pursue an ADLT path with improved pricing. Somewhat similar to what we did with tissue, but for tissue, our pricing is based on CDLT, it's not ADLT. There's a little confusion out there in the market on that. We feel very good about the price stability around our ASPs over the coming years. From a tailwind standpoint, obviously, MI Cancer Seek continues to perform very well, being the only FDA-approved whole exome, whole transcriptome assay out there. Caris Assure is continuing to excel as well because of the unique approach we're taking. We definitely think the gross margin is in a good space right now. One of the unique things about us as a company is we're never kind of focusing on the individual gross margin levels. What we want to do is focus on the technology. We never go in developing a technology to hit a certain gross margin. You want to get the best data and the best test out there, and then you actually operationalize and kind of fine-tune it after the fact. It's the same thing that we're taking with the Caris Detect. Whole genome is not a cheap test to do, but it will get you the best performance. That always has to be your primary focus anytime it's customer-focused or patient-focused. From a guidance standpoint, we maintained our guide based on the Q1 call. We feel very good about that today. One of the key things that we've pointed out is this is just based on the existing products that are out there at the end of Q1. Obviously, we've launched Caris MI Clarity, we've launched Caris ChromoSeq, and we're also planning on launching Detect. We'll add these to the guide once they have actually had a quarter or two to mature, and then continue to update The Street from there. I'll stop it there for questions. Great. Thank you so much. I think if you guys could walk through the share buyback that you announced this morning, what was the strategy, and then any other updates on how you're thinking about capital allocation? Yeah. Listen, I don't think it was anything other than a view that we have the capability, we have the profitability that Luke was talking about, and we have the ability to continue to invest in both the product pipeline, MCED launch, channel strengthening, et cetera. We have the free board, and given where the stock is, why not use it? I think it's also a reflection of our CEO and founder's confidence about this market and the company overall. Great. You mentioned the Detect launch earlier in the presentation. I guess maybe talk through what else you need to see in order to launch that test, how you're thinking about timing, and then also just how you're thinking about that market developing over time. You'll be launching as a self-pay, partnered with Everlywell, but any sort of updates there? We publicly announced that we're going to do the first launch with Everlywell, that online platform. I think what we're working through right now is just making sure the customer experience is excelling end-to-end. The focus on the IT systems, what the follow-ups are. We're in a unique position because of our history, that it's not just we don't want to give just a result test, and then if it's a yes, good look, no, you're good. We want to help the patient after the fact, too, after the result. We're doing now is finalizing all those processes and what's the next step. With the goal, we've communicated before in the first half of this year, so we're coming up on that. Again, the focus for us is always on the customer experience. We want to make sure that's right. From a next step standpoint, it's getting that online platform up and running, seeing what the initial uptick is, and then expanding partnerships. For us, we've shown the financial discipline as a company over the last couple of years, and we want to continue that with Detect, too. We're not going to hire a 300-person sales force, go PCP or anything like that. We're going to utilize the partnerships that are already out there. The healthcare space in itself, especially from people looking after their own health, is changing. People are taking care of themselves more. They're doing a lot more online. I think that's going to be the focus for us from a Detect launch standpoint. Great. I guess in the last 30 seconds, what do you feel is the most underappreciated part of the Caris story, and what are you most excited about as you move throughout the next year? I think the underappreciation is we've shown the profitability. That's very unique in our space. Also the technology. There's no one else doing whole exome, whole transcriptome at the scale that we're doing it. And now expanding into whole genome for Detect, I think that's very unique. It's not an easy thing to do. People think they can get a kit and they can run it. It's not. It takes a lot of years' experience to do it. I think the technology component is kind of lost a little bit. Great. We'll end it there. Thank you so much. Great. Thank you. Thanks, Evie. Yeah. Thanks, guys.